Lexeo Therapeutics (LXEO) Cash from Financing Activities (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Cash from Financing Activities data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 22190.91% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $219.2 million (up 164739.1% YoY), and the FY2025 full-year result was $216.8 million, up 144.2% from the prior year.
• Cash from Financing Activities fell to $2.5 million in Q1 2026, from $143.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $143.8 million in Q4 2025 to a low of -$98000.0 in Q1 2023.
• A 5-year average of $29.4 million and a median of $171500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 101.84% in 2024 and surged 148318.56% in 2025, its largest moves.
• Tracing LXEO's Cash from Financing Activities over 5 years: stood at -$81000.0 in 2022, then jumped by 123644.44% to $100.1 million in 2023, then plunged by 100.1% to -$97000.0 in 2024, then surged by 148318.56% to $143.8 million in 2025, then slumped by 98.29% to $2.5 million in 2026.
• Business Quant data shows LXEO's Cash from Financing Activities at $2.5 million in Q1 2026, $143.8 million in Q4 2025, and $52000.0 in Q3 2025.